Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141464 | 0.97 | — | — | |
| Sulfuric Acid SCHEMBL1556465 | 0.88 | BLM (0.55) | — | |
| SCHEMBL29145538 | 0.85 | LMNA (0.39) | — | |
| Hydrochloric Acid SCHEMBL3506692 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL1448173 | 0.79 | — | — | |
| SCHEMBL1446201 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL9985787 | 0.77 | DNM1 (0.43) | — | |
| Trifluoroacetic Acid SCHEMBL15049079 | 0.75 | LMNA (0.37) | — | |
| SCHEMBL460802 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL20482978 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117998946-A | Perovskite solar cell doped based on 2-aminoethyl methylsulfone hydrochloride and preparation method thereof | 吉林大学 | 2024-05-07 | — | — | CN | claimed |
| CN-115108949-A | Method for preparing 2- (methylsulfonyl) ethylamine hydrochloride by using methyl mercaptan | 江苏恒沛药物科技有限公司 | 2022-09-27 | — | — | CN | claimed |
| WO-2022029795-A1 | An environment friendly process for the preparation of Lapatinib Ditosylate of Formula 1(b) | SUMAR BIOTECH LLP (IN) | 2022-02-10 | — | — | WO | claimed |
| CN-110698417-B | Preparation method of 6-substituent furyl-4-substituted amino quinazoline derivative and key intermediate thereof | 新发药业有限公司 | 2020-11-20 | — | — | CN | claimed |
| WO-2020136671-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LAPATINIB BASE AND IT'S ANHYDROUS DITOSYLATE SALT | NATCO PHARMA LIMITED (IN) | 2020-07-02 | — | — | WO | claimed |
| CN-110698417-A | Preparation method of 6-substituent furyl-4-substituted amino quinazoline derivative and key intermediate thereof | 新发药业有限公司 | 2020-01-17 | — | — | CN | claimed |
| CN-105646405-B | The preparation method of substituted adjacent amido benzonitrile compound, preparation method and Lapatinib | 凯莱英医药集团（天津）股份有限公司 | 2018-12-11 | — | — | CN | claimed |
| CN-105738492-B | The method of impurity content in LC MS/MS combination measure Lapatinibs | 人福医药集团股份公司 | 2017-12-19 | — | — | CN | claimed |
| CN-107056661-A | A kind of preparation method of lapatinib intermediate 2 (methylsulfonyl) ethylamine hydrochloride | 山东铂源药业有限公司 | 2017-08-18 | — | — | CN | claimed |
| CN-105738492-A | Method for detecting impurity content in lapatinib through combination of LC-MS and MS | 人福医药集团股份公司 | 2016-07-06 | — | — | CN | claimed |
| CN-103030580-A | Preparation method of lapatinib intermediate | SHANDONG BOYUAN PHARMACEUTICAL CO LTD | 2013-04-10 | — | — | CN | claimed |
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-11-22 | — | — | US | claimed |
| EP-2489661-A1 | Impurity of lapatinib and salts thereof | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-08-22 | — | — | EP | claimed |
| CN-102321076-A | The preparation method of lapatinibditosylate midbody and analogue thereof | USTC UNIV SCIENCE TECH CN | 2012-01-18 | — | — | CN | claimed |
| EP-2305634-A1 | THE NEW PREPARATION OF ALIPHATIC AMINES WITH SULPHONYL GROUP AND THEIR SALTS | Knowa Pharmaceutical (Shanghai) Co. Ltd. (CN) | 2011-04-06 | — | — | EP | claimed |
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | claimed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | claimed |
| CN-1886397-A | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3) | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | claimed |
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | claimed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |